Literature DB >> 30559320

HBHA-Induced Polycytotoxic CD4+ T Lymphocytes Are Associated with the Control of Mycobacterium tuberculosis Infection in Humans.

Laetitia Aerts1, Elodie Selis1, Véronique Corbière1, Kaat Smits1, Anne Van Praet1, Nicolas Dauby2, Emmanuelle Petit3,4,5,6, Mahavir Singh7, Camille Locht3,4,5,6, Violette Dirix1, Françoise Mascart8,9.   

Abstract

Heparin-binding hemagglutinin (HBHA), a surface protein of Mycobacterium tuberculosis, is an attractive vaccine candidate and marker of protective immunity against tuberculosis, although the mechanisms underlying this protective immunity are not fully understood. Comparisons of the immune responses of latently M. tuberculosis-infected (LTBI) subjects to those of patients with active tuberculosis (aTB) may help to identify surrogate markers of protection, as LTBI subjects are most often lifelong protected against the disease. HBHA was shown to induce strong Th1 responses and cytotoxic CD8+ responses in LTBI subjects, but additional mechanisms of control of M. tuberculosis infection remain to be identified. In this study, using HBHA-induced blast formation as a readout of specific T lymphocyte activation, we report the presence in M. tuberculosis-infected subjects of HBHA-induced CD4+ T cell blasts that degranulate, as measured by surface capture of CD107a. This suggests the induction by HBHA of a CD4+ T cell subset with cytolytic function, and as nearly half of these cells also contained IFN-γ, they had both Th1 and cytotoxic characteristics. We further identified a CD4+ T lymphocyte subset producing IFN-γ together with a combination of mediators of cytotoxicity, i.e., perforin, granzymes, and granulysin, and we called them polycytotoxic CD4+ T lymphocytes. Interestingly, whereas purified protein derivative induced such cells in both LTBI subjects and patients with aTB, HBHA-specific polycytotoxic CD4+ T lymphocytes were detected in LTBI subjects and not in patients with pulmonary aTB. To our knowledge, we thus identified a new HBHA-induced CD4+ T cell subset that may contribute to the control of M. tuberculosis infection.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30559320     DOI: 10.4049/jimmunol.1800840

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Identification of antigens presented by MHC for vaccines against tuberculosis.

Authors:  Paulo Bettencourt; Julius Müller; Annalisa Nicastri; Daire Cantillon; Meera Madhavan; Philip D Charles; Carine B Fotso; Rachel Wittenberg; Naomi Bull; Nawamin Pinpathomrat; Simon J Waddell; Elena Stylianou; Adrian V S Hill; Nicola Ternette; Helen McShane
Journal:  NPJ Vaccines       Date:  2020-01-03       Impact factor: 7.344

Review 2.  Tuberculosis Vaccine Development: Progress in Clinical Evaluation.

Authors:  Suraj B Sable; James E Posey; Thomas J Scriba
Journal:  Clin Microbiol Rev       Date:  2019-10-30       Impact factor: 26.132

3.  Recombinant fusion protein of Heparin-Binding Hemagglutinin Adhesin and Fibronectin Attachment Protein (rHBHA-FAP) of Mycobacterium avium subsp. paratuberculosis elicits a strong gamma interferon response in peripheral blood mononuclear cell culture.

Authors:  Vida Eraghi; Abdollah Derakhshandeh; Arsalan Hosseini; Masoud Haghkhah; Leonardo A Sechi; Azar Motamedi Boroojeni
Journal:  Gut Pathog       Date:  2019-07-09       Impact factor: 4.181

4.  T Cell Receptor Repertoire Analysis Reveals Signatures of T Cell Responses to Human Mycobacterium tuberculosis.

Authors:  Ming-Ming Shao; Feng-Shuang Yi; Zhong-Yin Huang; Peng Peng; Feng-Yao Wu; Huan-Zhong Shi; Kan Zhai
Journal:  Front Microbiol       Date:  2022-02-07       Impact factor: 5.640

Review 5.  Mycobacterium tuberculosis Primary Infection and Dissemination: A Critical Role for Alveolar Epithelial Cells.

Authors:  Michelle B Ryndak; Suman Laal
Journal:  Front Cell Infect Microbiol       Date:  2019-08-21       Impact factor: 5.293

6.  Identification of antigens presented by MHC for vaccines against tuberculosis.

Authors:  Julius Müller; Annalisa Nicastri; Daire Cantillon; Nicola Ternette; Helen McShane; Paulo Bettencourt; Meera Madhavan; Philip D Charles; Carine B Fotso; Rachel Wittenberg; Naomi Bull; Nawamin Pinpathomrat; Simon J Waddell; Elena Stylianou; Adrian V S Hill
Journal:  NPJ Vaccines       Date:  2020-01-03       Impact factor: 7.344

7.  Diagnostic performance of culture filtered protein 10-specific perforin in pediatric patients with active tuberculosis.

Authors:  Qinzhen Cai; Xin Shen; Hongze Li; Cong Yao; Na Sun; Jun Wang; Huan Wu; Chunhui Yuan; Jie Xiang; Yun Xiang
Journal:  J Clin Lab Anal       Date:  2020-07-16       Impact factor: 2.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.